Novel Cell-Type Therapeutic Platforms in Oncology (Part II) A Cell by Any Other Name...Does Not Work the Same from yescarta car t cell therapy Watch Video
Preview(s):
Gallery
Play Video: (Note: The default playback of the video is HD VERSION. If your browser is buffering the video slowly, please play the REGULAR MP4 VERSION or Open The Video below for better experience. Thank you!)
Description: Moderator:nJoel Sandler, PhD, Principal and Practice HeadnnPanelists:nDebora Barton, MD, CMO, Carisma TherapeuticsnCharles Nicolette, PhD, CEO, CoImmune Inc.nKimberly Noonan, PhD, MPH, EVP, CSO and Founder, WindMIL TherapeuticsnnPerhaps more so than any other modality to date, cancer cell therapies have captured the imaginations and wherewithal of industry, investor, and oncologist communities alike. A fundamental but often vaguely understood component of emerging cell therapy platforms is the
Play Video: (Note: The default playback of the video is HD VERSION. If your browser is buffering the video slowly, please play the REGULAR MP4 VERSION or Open The Video below for better experience. Thank you!)